



(51) International Patent Classification:

C07D 401/14 (2006.01) *A61P 13/10* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/US2015/047415

(22) International Filing Date:

28 August 2015 (28.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2014/085925
4 September 2014 (04.09.2014) CN

(71) Applicant: **ELI LILLY AND COMPANY** [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(71) Applicant (*for MG only*): **LILLY CHINA RESEARCH
AND DEVELOPMENT CO., LTD.** [CN/CN]; 780
Cailun Road, R. 819, Zhangjiang High, Technology Park,
Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **HUANG, Ping**; c/o Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).
RIBE, Seth Dietrich; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **WINTER, Mark A.** et al.; c/o Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AF, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BI, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GI, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE (2S)-3-[(3S,4S)-3-[(1R)-1-HYDROXYETHYL]-4-(4-METHOXY-3-[[1-(5-METHYLPYRIDIN-2-
YL)AZETIDIN-3-YL]OXY]PHENYL)-3-METHYLPYRROLIDIN-1-YL]-3-OXOPROPANE-1,2-DIOL

(57) Abstract: The invention provides crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-[[1-(5-methylpyridin-2-
yl)azetidin-3-yl]oxy]phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol, and pharmaceutical compositions thereof. The inven-
tion further provides methods of using this compound to treat overactive bladder.

